Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Open-label, Single-arm Phase Ⅱ Clinical Trial of TQ-B3101 in Subjects With Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

Next Previous
Search
Trial Profile

A Open-label, Single-arm Phase Ⅱ Clinical Trial of TQ-B3101 in Subjects With Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Unecritinib (Primary)
  • Indications Anaplastic large cell lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

    • Most Recent Events

    • 13 Dec 2022 Results (n=7; As of the cut-off date of July 22, 2022) assessing the safety and efficacy of TQ-B3101 in pediatric patients with anaplastic lymphoma kinase positive anaplastic large cell lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 18 Mar 2022 Data from this and a phase 1 study was used to develop population pharmacokinetic (PK) model to characterize the PK of TQ-B3101 and its active metabolite TQ-B3101M after oral dosing of TQ-B3101, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 16 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top